EIDBI Autism Fraud: DOJ Charges Smart Therapy and Star Autism Owners in $46.6M Indictment
A federal grand jury indicted Shamso Ahmed Hassan and Hanaan Mursal Yusuf in the largest Medicaid autism fraud case ever charged by DOJ. The $46.6 million scheme allegedly defrauded Minnesota's EIDBI Program through hidden ownership, kickbacks to parents disguised with the code word "computer," and billing for services that were never provided.
Minnesota HSS Program Fraud: $15.7M Medicaid Takedown
The Justice Department charged eight defendants in the Minnesota Housing Stabilization Services Program Medicaid fraud takedown, alleging $15.7 million in false claims. The four cases reveal the federal charging theories now driving Medicaid waiver enforcement nationwide, including fraud tourism, conspiracy under 18 U.S.C. section 1349, and substitute asset forfeiture. Former DOJ Fraud Section prosecutors Scott Armstrong and Drew Bradylyons analyze the indictments.
Mailyan $45M Botox Fraud Conviction: Defense Analysis
A federal jury convicted Dr. Violetta Mailyan on May 18, 2026, of nine counts of wire fraud and three counts of obstruction in a $45M Medicare Botox scheme. Former DOJ Fraud Section prosecutors break down the jury instructions and data analytics origin.
The Anti-Kickback Statute Is Central to Federal Healthcare Fraud Enforcement in 2026
Federal Anti-Kickback Statute defense by former DOJ Healthcare Fraud Unit Assistant Chiefs. Elements, safe harbors, defenses, and trial strategy under 42 USC 1320a-7b.
Skin Substitute Fraud Defense: U.S. v. Ellsworth Analysis
Defense analysis of the May 2026 Ellsworth skin substitute fraud indictment. Analysis of the indictment, which includes No kickback counts, and medical necessity allegations.
DOJ Launches West Coast Health Care Fraud Strike Force: Federal Investigations in Arizona, Nevada, and Northern California
DOJ's Fraud Division announced the West Coast Health Care Fraud Strike Force on April 30, 2026, covering the District of Arizona, District of Nevada, and Northern District of California. Analysis of the $1.2 billion wound graft fraud prosecution, the $100 million Adderall telehealth fraud conviction, and the $650 million substance abuse Medicaid fraud indictment driving the expansion. How Strike Force investigations are built through data analytics, grand jury subpoenas, covert search warrants, and cooperating witnesses. Criminal statutes charged in Strike Force indictments including 18 U.S.C. 1347, the Anti-Kickback Statute, EKRA, and 21 U.S.C. 841. Defense considerations for individuals under investigation or facing indictment in Strike Force districts.
SEC v. Patel: Market Manipulation Through Spoofing and Layering, Federal Charges, and Defense Considerations
The SEC charged day trader Harsh Patel with manipulating more than 400 securities through spoofing and layering. Analysis of the three federal counts, their elements under SDNY authority, and defense considerations including scienter, non-bona fide order characterization, liability causation, and parallel criminal exposure.
Federal Healthcare Fraud and Illegal Prescribing Charges: Intent, Medical Necessity, and Defense Strategies
Missouri physician indicted on 38 federal counts combining healthcare fraud with illegal prescribing of Adderall, benzodiazepines, and hydrocodone. Analysis of the government's burden on intent after Ruan v. United States, medical necessity defenses for non-opioid controlled substances, supervision fraud theories under 18 U.S.C. § 1347, and why trial readiness matters in dual-theory prosecutions. By former DOJ ARPO Strike Force director.
OneCoin Fraud Victim Claims: How to File for DOJ Compensation Before the June 2026 Deadline
The DOJ opened a $40 million compensation process for OneCoin fraud victims. Claims must be filed by June 30, 2026 at onecoinremission.com. This guide explains who is eligible under 28 C.F.R. Part 9, what documentation is required, how recovery amounts are calculated, and the criminal exposure risks for OneCoin promoters.
FDA Warning Letters on Exosome Products | Regulatory & Criminal Defense
FDA warning letters to exosome manufacturers cite unapproved drugs, unlicensed biologics, and misbranded products under the FD&C Act and PHS Act. Analysis of enforcement trends from 2024 through 2026, criminal prosecution risks, and the regulatory framework for exosome products. Defense by former senior DOJ officials.
CFTC Oil Futures Investigation: Insider Trading Charges and Defense
Former DOJ Fraud Section prosecutors analyze the CFTC oil futures investigation, Tag 50 exchange data, commodities fraud charges under the CEA, and defenses.
Home Health Certification in Federal Fraud Cases: OASIS, Homebound Status, Face-to-Face Encounter
Analysis of the Medicare home health certification process in federal criminal fraud cases. Covers the face-to-face encounter under 42 C.F.R. 424.22, OASIS assessment scoring under PDGM, homebound status certification, CMS-485 physician certification, LCD compliance, and defense strategies including cross-examination of beneficiary witnesses who received undisclosed kickback payments. By former DOJ Fraud Section prosecutors.
DOJ Creates the National Fraud Enforcement Division: What It Means for Federal Procurement Fraud Defense
On April 7, 2026, Acting Attorney General Todd Blanche established the National Fraud Enforcement Division. Analysis of the new division, recent criminal procurement fraud cases, the statutes DOJ uses, and the key defenses available to individuals facing investigation or indictment.
Operation Never Say Die: Federal Hospice Fraud Arrests and CMS Payment Suspensions
Eight defendants arrested and 221 hospice providers suspended in Operation Never Say Die. Analysis of the federal charges, CMS payment suspension procedures under 42 C.F.R. 405.371, and the strategic risks of responding to a suspension notice while a parallel DOJ criminal investigation may be active.
Clawback Demands: Coming soon from the Goliath Ventures Case
Clawback defense for Goliath Ventures investors, vendors, and professionals. Scott Armstrong and Drew Bradylyons, founders of Armstrong & Bradyylons PLLC and former senior DOJ officials, explain the receiver's theories, challenges, and strongest available defenses.
Injection Fraud Is a Federal Enforcement Priority: Charges, Defenses, and What Providers Need to Know
DOJ and HHS-OIG are aggressively targeting injection fraud in 2025 and 2026. Facet joint injections, Botox, trigger point injections, and epidural steroid injections billed to Medicare are under direct federal scrutiny. This guide covers the key federal charges, defenses, and billing codes at issue. Armstrong & Bradylyons PLLC defends physicians and healthcare executives in federal injection fraud investigations nationwide.
Hospice Fraud: On the Law-Enforcement Horizon
Federal hospice fraud investigations are escalating in 2025 and 2026. Scott Armstrong and Drew Bradylyons, two former Assistant Chiefs at DOJ’s Fraud Section, explain the scrutiny, investigations, and charges that hospice executives and certifying physicians face in these cases.